Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 15 the optimal add-on than without it. For the Foster NEXaler, a consistent increase was achieved only at lower flow rates, whereas the Trelegy Ellipta exhib- ited the most stable maximum relative enhance- ment, ranging from 35% to 38%. ese relatively e greatest enhancement in lungdeposited dose occurred with the Symbicort Turbuhaler, particu- larly at higher flow rates, where the maximum rela- tive increase reached 160%, meaning that the mass of drug entering the lungs was 2.6 times higher with Figure 5 Maximum values of the relative increase of drug mass reaching the lungs due to add-ons for the Ultibro ® Breezhaler ® , Symbicort ® Turbuhaler ® , Foster ® NEXThaler ® and Trelegy ® Ellipta ® DPIs at 30, 60 and 90 L/min inhalation flow rates. The add-ons providing the maximum values of the relative change are named above the bars. 160 140 120 100 80 60 40 20 0 Relative increase of drug mass to the lungs (%) Ultibro® Breezhaler® Symbicort® Turbuhaler® Foster® NEXThaler® Trelegy® Ellipta® cone_0 cone_3 cone_3 cup_0 cup_0 cup_4 cup_4 cup_4 cup_0 cup_0 cone_6 Add-on Drug 30 L/min 60 L/min 90 L/min Drug 30 L/min 60 L/min 90 L/min cone_0 Ultibro ® Breezhaler ® 3.4 -11.2 4.0 Symbicort ® Turbuhaler ® -25.6 29.1 22.7 cone_3 6.1 -16.4 27.7 -20.0 33.5 -45.6 cone_4 1.6 -9.5 12.7 -10.2 110.2 4.2 cone_6 3.9 -6.1 30.8 -38.6 10.5 -52.2 cup_0 0.1 5.6 5.8 -19.3 160.1 68.1 cup_4 1.2 -6.9 -13.0 -17.7 41.5 44.6 cone_0 Foster ® NEXThaler ® 22.9 -13.4 -33.9 Trelegy ® Ellipta ® 23.6 10.1 13.9 cone_3 29.0 -6.6 12.5 21.6 7.6 15.3 cone_4 26.8 -15.6 -14.3 17.4 8.4 18.3 cone_6 36.1 -18.2 0.3 11.2 -2.1 15.9 cup_0 44.9 -4.7 -11.9 21.7 37.9 35.3 cup_4 48.6 6.8 -12.5 38.1 21.3 25.9 Table 1 Changes in the drug mass reaching the lungs due to different add-ons relative to the cases without any add-on. All values are expressed in percent. Flow rate 30 L/min 60 L/min 90 L/min

